ARYx Therapeutics Inc
OTC:ARYX

Watchlist Manager
ARYx Therapeutics Inc Logo
ARYx Therapeutics Inc
OTC:ARYX
Watchlist
Price: 0.0005 USD Market Closed
Market Cap: 33.5 USD

ARYx Therapeutics Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

ARYx Therapeutics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
ARYx Therapeutics Inc
OTC:ARYX
Operating Income
-$31.2m
CAGR 3-Years
-3%
CAGR 5-Years
-8%
CAGR 10-Years
N/A
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.9B
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
3%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$16.1B
CAGR 3-Years
11%
CAGR 5-Years
22%
CAGR 10-Years
19%
Pfizer Inc
NYSE:PFE
Operating Income
$18.3B
CAGR 3-Years
-23%
CAGR 5-Years
12%
CAGR 10-Years
3%
Merck & Co Inc
NYSE:MRK
Operating Income
$24.5B
CAGR 3-Years
7%
CAGR 5-Years
27%
CAGR 10-Years
11%
Eli Lilly and Co
NYSE:LLY
Operating Income
$26.4B
CAGR 3-Years
46%
CAGR 5-Years
34%
CAGR 10-Years
22%
No Stocks Found

ARYx Therapeutics Inc
Glance View

Market Cap
33.5 USD
Industry
Pharmaceuticals

ARYx Therapeutics, Inc. discovers and develops drugs for large, chronic disease markets. The company is headquartered in Fremont, California and currently employs 56 full-time employees. The company went IPO on 2007-11-08. The firm is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. The company is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.

ARYX Intrinsic Value
Not Available

See Also

What is ARYx Therapeutics Inc's Operating Income?
Operating Income
-31.2m USD

Based on the financial report for Dec 31, 2009, ARYx Therapeutics Inc's Operating Income amounts to -31.2m USD.

What is ARYx Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-8%

Over the last year, the Operating Income growth was -3%. The average annual Operating Income growth rates for ARYx Therapeutics Inc have been -3% over the past three years , -8% over the past five years .

Back to Top